High IL‐17A identified more patients who meet clinical study endpoints of antibiotic failure than were identified by infective endocarditis diagnosis, offering potential utility as risk stratification biomarkers to facilitate patient selection for clinical trials. The gene discussed is IL17A; the disease is infective endocarditis.